A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Source: CNBC
Original reporting
CNBC: read the full reportRelated stories
CNBC
American embassies tighten security as Iran threat warnings intensify ahead of U.S. midterm elections
A memo from DNI director Jay Clayton said Iran is in the "advanced stages" of planning attacks against Americans.
CNBC
Why popular airplanes are getting scrapped years early
Airplanes are getting dismantled for parts years ahead of schedule because engines and other components are in short supply.
CNBC
Retail investors are not more sophisticated than 30 years ago, says former hedge fund manager
Retail investors trying to beat the market by buying individual stocks and complex exchange-traded funds may be better off with broad market index funds.
CNBC
I quit my marketing job to walk dogs for 4 months: It's 'one of the most valuable professional experiences I've ever had'
"People sometimes assume dog walking was a gap or detour in my career. I see it as one of the most valuable professional experiences I've had," says Sally Simmons.
CNBC
An ex-bookkeeper spent $375 to launch a sewing business: 'I hadn't felt so sure about something like that in a long time'
Eric Lugo runs Stitch Lab ATX, a sewing studio that offers group classes and events to teach basic sewing skills.
CNBC
Fact vs. fiction: Doctors share whether peptides are safe and effective
As peptides gain popularity among some wellness influencers and federal government officials, doctors share what you need to know.